CLU and hepatocellular carcinoma: Therefore, further to the research indicating the involvement of clusterin in the regulation of the Akt pathway and oxaliplatin response in hepatocellular carcinoma (HCC) [37], we conducted experiments to demonstrate the correlation between clusterin and oxaliplatin resistance.